| Id: | acc3778 |
| Group: | 1sens |
| Protein: | ERK1 |
| Gene Symbol: | Mapk3 |
| Protein Id: | P21708 |
| Protein Name: | MK03_RAT |
| PTM: | phosphorylation |
| Site: | Tyr204 |
| Site Sequence: | EHDHTGFLTEYVATRWYRAPE |
| Disease Category: | Nervous system diseases |
| Disease: | Cerebral Damage |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Ketamine |
| Drug Info: | Ketamine is an anesthetic and has also been used as a recreational drug. It can cause dissociative effects. |
| Effect: | modulate |
| Effect Info: | Ketamine → Inhibition of NMDA - R/Ca?? influx → Decreased phosphorylation of ERK1/2 → Mitigation of cerebral damage exacerbated by hyperglycemia |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 17870450 |
| Sentence Index: | 17870450_9 |
| Sentence: | "The inhibitory effects of ketamine on the hyperglycemia-activated ERK1/2 phosphorylation are probably through inhibition of the N-methyl d-aspartate-mediated calcium influx, which subsequently reduce the hyperglycemia-exaggerated cerebral damage." |
Sequence & Structure:
MAAAAAAPGGGGGEPRGTAGVVPVVPGEVEVVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRAPTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFDMELDDLPKERLKELIFQETARFQPGAPEAP
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 203 | D | Major depressive disorder | Phosphorylation | 16959794 |
| Y | 205 | D | Major depressive disorder | Phosphorylation | 16959794 |
| T | 203 | U | Uteroplacental insufficiency | Phosphorylation | 16940436 |
| Y | 205 | U | Uteroplacental insufficiency | Phosphorylation | 16940436 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
